Dr. Moro,
Please explain why the front door at Biocurex / Pacific Biosciences has not been knocked down by the stampede of large diagnostic companies and the FDA to fast track Recaf in efforts to get it on the market by "Yesterday". I can see the results listed below. They look fantastic and yet we seem to stand still in a state of flux waiting on big companies such as Inverness and Abbott to wake up.
On one hand we have these great results and on the other hand we continue to wait for a third licensee and for Abbott and Inverness to even acknowledge that we still exist following the signing of the agreements.
We have all been very patient. I have to admit that I do not understand the process of validation / approval etc... What I would like to know though is are we looking for Inverness / Abbott to be ready in a month...A year...5 years ? Are they busy drinking coffee and and playing golf with the FDA or are they actively readying Recaf for FDA trials....Completed with trials and packaging the tests for sales... or are we still waiting for them to open up the initial Biocurex agreement to begin assembling the project team to see if Recaf can do what the company says it can do? Biocurex gets the quarterly reports but the shareholders have been waiting years for some sort of acknowlegement.
Below are the results posted from your recent trip to Spain. I get very excited seeing these results but am floored that we are not on every front page of every newspaper in the world exploiting these results. What am I missing?
XII INTERNATIONAL SYMPOSIUM ON BIOLOGY AND CLINICAL USEFULNESS
OF TUMOR MARKERS
L-33) RECAF AS A ‘UNIVERSAL’ TUMOR MARKER AND ITS
USEFULNES FOR EARLY CANCER DETECTION
Ricardo Moro
BioCurex Inc. 7080 River Rd. Richmond, B.C., Canada V6X 1X5,
rmoro@.biocurex.comAlpha-fetoprotein (AFP) is a circulating glycoprotein highly expressed during
embryonic development but almost absent from normal adult serum. Most fetal
cells - but not normal adult cells - express a receptor for AFP (RECAF) during
differentiation. It is believed that this receptor plays a role in the uptake of polyunsaturated
fatty acids transported by AFP into fetal cells. Normal adult cells do
not uptake AFP, but cancer cells of all major cancers types studied do, and they reexpress
RECAF, which is shed into the circulation of patients with malignancies.
We have developed RECAF assays (RIA, chemiluminescence and ELISA) to measure
circulating RECAF. Studies conducted in our laboratory and others have shown
that this marker is increased in most cancers.
Further studies on breast and
prostate cancers have also shown that early stages (I and II) can be detected with
high specificity and sensitivity, even when compared to benign lesions. The Table
below summarizes the results for several cancer types using the different assay
formats.
Cancer type Sensitivity Specificity
Lung vs. normal 90% 100%
Liver vs. normal 100% 94%
Stomach vs. normal 90% 98%
Ovarian vs. normal 75% 98%
Colorectal vs. normal 100% 93%
Prostate cancer vs. normal
Stage I 70% 100%
Stage II 76% 100%
Stage III 85% 100%
Stage IV 86% 100%
Prostate cancer vs. BPH (Stages I & II) 75% 90%
Breast cancer Stages I & II vs. normal 93% 98%
Breast cancer Stages I & II vs. benign 72% 85%
- 41 -
The results suggest that: (a) RECAF could be used for screening for early stages of
cancer, (b) using RECAF in combination with other markers such as PSA, CEA, etc
as well as mammographies or ultrasound could prove beneficial, (c) that RECAF
could be used to monitor therapy and follow up patients after treatment.In
addition, preliminary results suggest that RECAF is also augmented in the saliva
of cancer patients and that a blood rapid test to be used at the doctor’s office also
detects an increased amount of RECAF in cancer patients. While these two
formats have lower sensitivity/specificity than the serum tests, they would make
screening more accessible, with ulterior verification of positive cases by the
clinical laboratory using a higher performance RECAF serum assay.
